Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904562 · ClinicalTrials.gov registry record · Phase 4
Angiotensin II for Distributive Shock
A Phase 4 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT04904562 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT04904562, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of 40 patients who develop distributive shock, intra-operatively or post-operatively within 48 hours of heart transplant or left ventricular assist device placement will be enrolled. Participants will be randomized to Angiotensin II (Giapreza) vs. placebo plus standard of care, as a first line agent for vasoplegia. Two groups of patients will be enrolled: * Group A: Heart Transplant (10 control, 10 treatment) * Group B: LVAD implant (10 control, 10 treatment)
Interventions
- DRUG Placebo
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904562
The ClinicalTrials.gov registry entry for NCT04904562 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04904562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04904562 about?
NCT04904562 is a clinical study titled "Angiotensin II for Distributive Shock". This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of 40 patients who develop distributive shock, intra-operatively or post-operatively within 48 hours of heart transplant or left ventricular assist device placement will be enrolled. Participants will be rando...
What is the current status of trial NCT04904562?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2022-06-01. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT04904562?
The interventions under investigation include: Placebo (DRUG), Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT04904562?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.